Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

CH1242303498
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG01BJ1BHZ3
OCS
Oculis Holding AG
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology
NAME
Oculis Holding AG
ISIN
CH1242303498
TICKER
OCS
MIC
XNAS
REUTERS
OCS.OQ
BLOOMBERG
OCS US
Tue, 21.04.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the invitation to the 2026 Annual General Meeting, which will be held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 6:00 a.m. EDT / 10:00 a.m. GMT / 12:00 p.m. CEST....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the invitation to the 2026 Annual General Meeting, which will be held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 6:00 a.m. EDT / 10:00 a.m. GMT / 12:00 p.m. CEST....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.04.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced completion of the final patient visit in the OCS-01 Phase 3 DIAMOND p...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.04.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced completion of the final patient visit in the OCS-01 Phase 3 DIAMOND...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.04.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, April 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, April 07, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in upcoming invest...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that its neuroprotective candidate Privosegtor has been granted Prio...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 31.03.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that its neuroprotective candidate Privosegtor has been granted Prior...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, March 27, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to annual equity incentive awards granted to a member of the executive committee of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, 16 March, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the presentation of the ACUITY Phase 2 data with Privosegtor at the North American Neuro...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 16.03.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the presentation of the ACUITY Phase 2 data with Privosegtor at the N...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the purchase of ordinary shares by a member of the Company’s Board of Directors....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 13.03.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, March 13, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a member of the executive committee of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.03.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, March 11, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to annual equity incentive awards granted to members of the executive committee of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 06.03.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, March 06, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.03.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in upcoming invest...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.03.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated financial statements for the financial year 2025 and the MD&A, which have now been filed with the SEC on form 20-F, are attached....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.03.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in upcoming invest...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.03.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, March 03, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the fourth quarter and full year ended December 31, 2025...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.03.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, March 3, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the fourth quarter and full year ended December 31, 2025, and provided an ove...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 27.02.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, Feb. 27, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.02.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.02.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced the appointment of Katie Kazem as Chief Legal Officer, leading Ocul...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.02.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, February 17, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced the appointment of Katie Kazem as Chief Legal Officer, leading Oculis’ legal, compl...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.01.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that the transformative potential of its late-stage pipeline, includ...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.01.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that the transformative potential of its late-stage pipeline, inclu...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 06.01.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- ZUG, Switzerland, January 6, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced that its neuroprotective candi...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 06.01.2026       Oculis Holding
CH1242303498

ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced that its neuroprotective candidate Privosegtor was granted breakthr...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.12.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.12.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 28.11.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.11.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company’s Board of Directors....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.11.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the third quarter ended September 30, 2025, and provided...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.11.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the third quarter ended September 30, 2025, and provide...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.11.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced today that Oculis’ management will participate in upcoming investor confer...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.11.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced today that Oculis’ management will participate in upcoming investor confer...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.10.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the pricing of offerings of an aggregate of 5,432,09...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.10.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the pricing of offerings of an aggregate of 5,432,09...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.10.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The attached two notifications relate to the exercise of vested stock options to purchase ordinary shares previously granted to a director of the Company, and the subsequent sale of those ordinary shares. These transactions were entered into pursuant to a 10b5-1 trading plan, in accordance with...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.10.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis’ innovative late-stage pipeline will be highlighted at Eyece...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.10.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis’ innovative late-stage pipeline will be highlighted at Eyece...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.10.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.10.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.10.2025       Oculis Holding
CH1242303498

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Fri, 26.09.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.09.2025       Oculis Holding
CH1242303498

Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Doub...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.09.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial...
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.09.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.09.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced, in collaboration with EURETINA, the winner of the Ramin Tadayoni Award 2025....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink
Thu, 04.09.2025       Oculis Holding
CH1242303498

ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced, in collaboration with EURETINA, the winner of the Ramin Tadayoni Award 2025....
Read more
Oculis Holding
Technical Analysis Termsheets Terminal
Permalink